Oxford-Harrington Rare Disease Centre
@oxfordharrington.bsky.social
Partnership of the University of Oxford and Harrington Discovery Institute. Combining expertise in discovery science and therapeutics development to accelerate cures for rare diseases.
Visit us at: www.oxfordharrington.org
Visit us at: www.oxfordharrington.org
Read more: www.oxfordharrington.org/events-news/...
September 17, 2025 at 6:03 PM
Read more: www.oxfordharrington.org/events-news/...
His approach equips CAR-T cells with molecular “switches” — offering doctors precise control and new hope for children with cancer.
September 17, 2025 at 6:03 PM
His approach equips CAR-T cells with molecular “switches” — offering doctors precise control and new hope for children with cancer.
Professor Louis Chesler, 2024 OHC Rare Disease Scholar, is developing regulatable CAR-T therapies that could transform treatment for children with brain tumours.
September 17, 2025 at 6:03 PM
Professor Louis Chesler, 2024 OHC Rare Disease Scholar, is developing regulatable CAR-T therapies that could transform treatment for children with brain tumours.
Although still in development, this new approach has the potential to finance a number of rare disease trials and advance treatments that might otherwise remain out of reach.
June 25, 2025 at 3:34 PM
Although still in development, this new approach has the potential to finance a number of rare disease trials and advance treatments that might otherwise remain out of reach.
Their approach, Patient Powered Research, involves matching promising yet currently unfunded trials with potential donors.
Professor Matthew Wood, Director of the OHC, says: ‘We see great potential – and indeed necessity – in enabling patients or their families to help fund early-stage trials.’
Professor Matthew Wood, Director of the OHC, says: ‘We see great potential – and indeed necessity – in enabling patients or their families to help fund early-stage trials.’
June 25, 2025 at 3:34 PM
Their approach, Patient Powered Research, involves matching promising yet currently unfunded trials with potential donors.
Professor Matthew Wood, Director of the OHC, says: ‘We see great potential – and indeed necessity – in enabling patients or their families to help fund early-stage trials.’
Professor Matthew Wood, Director of the OHC, says: ‘We see great potential – and indeed necessity – in enabling patients or their families to help fund early-stage trials.’
This is why patient advocates Dominic Nutt and Alexander Masters are developing new routes for funding trials that could help families, such as Cure DHDDS's trustee Melanie Dixon and two of her children, Tom and Rosie, who have a DHDDS genetic mutation.
June 25, 2025 at 3:34 PM
This is why patient advocates Dominic Nutt and Alexander Masters are developing new routes for funding trials that could help families, such as Cure DHDDS's trustee Melanie Dixon and two of her children, Tom and Rosie, who have a DHDDS genetic mutation.